Company Update Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Company Update
Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Disclaimer
This article is for informational purposes only and is not investment advice. Verify all figures and announcements from official exchange filings and company disclosures before making decisions.
Quick Notification
Smart analysis of market trends
Notifications on crucial events
Alerts in the chat you already use
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.
"ZTOX has transformed how I track companies. The real-time alerts and AI insights save me hours of research every day."
— Aditya M., Active Trader